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ABSTRACT
Objective: The goal of this research was to study fragmentation pathways of series salts of 1,2,4-triazolylthioacetate acids.
Methods: The study was done in the Electrospray ionization source with single quadrupole mass spectrometer Agilent 6120 after elution through 
column Zorbax SB-C18, 30 mm × 4.6 mm, 1.8 µm at Agilent 1260 infinity high-performance liquid chromatography system. The series salts of 
1,2,4-triazolylthioacetate acids were studied. These salts are active pharmaceutical ingredients of potential or registered pharmaceutical formulations.
Results: The mass spectra of corresponding compounds have analyzed. The fragmentation patterns of these compounds decay have proposed.
Conclusions: Studying the fragmentation of the indicated substances can be used for detecting the mentioned substances, as well as for confirming 
the structure of new compounds with the mass spectrum based on the patterns described above.
Keywords: Mass spectrometry, Electrospray ionization, High-performance liquid chromatography, Salts of the 1,2,4-triazolylthioacetate acids.
INTRODUCTION
Derivatives of 1,2,4-triazoles are potential medicinal substances with 
diverse biological activity. They have antiviral, hepatoprotective, 
cardioprotective, immunomodulatory, interferonogenic, antioxidant, 
anti-inflammatory, neuroprotective, hepatoprotective, and other 
activities; moreover, some of them are already registered and used in 
the present-day veterinary (tryfusol and avesstim) and one of them 
are on the stage of registration for human use and manufacturing 
application (thiometrizol).
Development of methods for active pharmaceutical ingredients of 
1,2,4-triazole derivatives determination in substances, pharmaceutical 
dosage forms, and biologic fluids is an important and urgent task.
The modern pharmaceutical analysis is characterized by prevailing of 
chromatographic methods, in particular, liquid chromatography (LC) 
with ultraviolet, diode array, and mass spectrometric detection.
Initially, chromatographic behavior [1] and behavior of substances in 
the ionic source [2] to optimize the conditions for defining data of active 
pharmaceutical ingredients were studied.
To describe the structure, identify, and quantify the substances with the 
help of high-performance LC–mass spectrometry (MS), it is necessary 
to know how compounds are fragmented in the ionic source.
There are many scientists that use mass spectrometric studies for 
confirmation of molecular mass and structure. For example, Philip et al. 
studied 1,2,4-triazole derivatives [3].
The electrospray LC-mass spectrometry (ESI-LC-MS) testing of the 
synthesized compounds confirmed the formation of the novel bis 
1,2,4-triazoles [4].
1,2,4-triazoles were studied in the research of Kaplaushenko et al. [5].
There are works that study patterns of mass spectrometric 
decompositions of 1,2,4-triazole derivatives. Thus, for example, the 
Salgın-Gökșen et al. offered the fragmentation patterns of 1,2,4-triazole-
5(4)-thiones series. It describes both the release of a substitute radical 
in a triazole cycle and partial disintegration of substituents [6].
The article İl, Küçükgüzel et al. showed fragmentation patterns 
including partial destruction of triazole cycles with the formation of 
tripartite diazo heterocyclic radical cations [7].
Similar structures are also described in the research Gülerman et al. [8].
Alternative options for decomposition of 1,2,4-triazole derivatives are 
offered by the authors of Eswaran et al. [9].
Possible variants of decomposition of 1,2,4-triazoles are also discussed 
in the article [10].
The goal of our research was to study the mass spectrum resulted from 
ESI in the area of collision induced dissociation by a single quadrupole 
mass spectrometer and offers fragmentation patterns of series of active 
pharmaceutical ingredients, derivatives, 1,2,3-triazole-ylthio-acetate 




High performance LC (HPLC) system Agilent 1260 Infinity (degasser, 
binary pump, autosampler, quadrupole mass spectrometer detector 
Agilent 6120 with ESI).
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Compounds
There were used substances, which were synthesized in Zaporozhye 
State Medical University at the toxicological and inorganic chemistry 
department, physical and colloid chemistry department. The 
composition of compounds was proved by elemental analysis and 
infrared, ultraviolet (UV), 1H-NMR spectroscopy, and chromatography 














Acetonitrile HPLC gradient grade from Merck KGaA (Darmstadt, 
Germany), formic acid (100%) from Merck KGaA (Darmstadt, 
Germany). Highly purified water (18 MΩ under 25°C) was produced 
with the usage of the system Direct Q 3UV Millipore (Molsheim, France).
Sample solutions
Solutions of compounds 1–6 were prepared by dissolving in 
50% acetonitrile, compound 7 in dimethyl sulfoxide to a final the 
concentration of 1 mg/mL.
Software
The package OpenLAB CDS software was used for 
acquisition. The Software packages ChemSketch ACDlabs 
12.0, ChemBioOffice 2012 were used for demonstration of the 
fragmentation patterns.
HPLC–MS conditions
The chromatography separation was done in isocratic mode at flow rate 
0.4 mL/min. The eluent consist on the water and acetonitrile (50:50) with 
0.1% of methanoic acid. Column was Zorbax SB-C18, 30 mm × 4.6 mm, 
1.8 µm. Column temperature was 40°. The ion source was atmospheric 
pressure ionization (API)-ES. The mass spectrometric detection was 
dine at positive polarity. The drying gas rate (nitrogen) was 10 L/
min . The capillary voltage of ESI was 4000 В. The mass spectrometric 
detection was done in SCAN mode at m/z range 100–1000.
ESI-MS conditions have proposed earlier showed in Table 1 [2].
RESULTS AND DISCUSSION
The mass spectra were presented in graphical and tabular form, with 
the providing of the most intensive peaks starting about 1%. The 
maximal peak from isotope pattern peaks was shown. We have analyzed 




There are mass spectra at Fig. 1 and Table 2.
In the acidic medium of an eluent, the salt form of the active 
pharmaceutical ingredient turns into acid form which was protonated 
on triazole nitrogen and forms a quasimolecular cation with m/z 
343 (Fig. 2). Cations with m/z 313 appear with the release of the 
oxymethyl group and 299 with the release of carbon oxide (IV) from a 
quasimolecular cation in case of both 100 V and 200 V. When the bond 
between sulfur and carbon of the triazole cycle was broken at 200 V, 
the cation with m/z 251 was formed. With further release of oxymethyl 
Table 2: The values of ions’ m/z of morpholin-4-ium 
2-((4-(2-methoxyphenyl)-5-(pyridin-4-yl)- 
4H-1,2,4-triazol-3-yl) thio) acetate ions and relative abundance 
at 100 V and 200 V
100 V 200 V
m/z Abundance, % m/z Abundance, %
299.10 2.8 105.10 34.7
313.00 2.6 119.10 2.7
343.00 100.0 132.10 9.7
344.10 19.0 149.10 1.6
357.00 3.7 178.00 1.7















Fig. 1: Mass spectra of the morpholin-4-ium 
2-((4-(2-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)
thio)acetate at 100 and 200 V
Table 1: ESI-MS conditions
Compound [MH]+ m/z Drying gas temperature, T Nebulizer pressure, psig
1 343 300 53
2 302 247 46
3 237 300 50
4 335 300 52
5 273 228 57
6 287 300 10
7 266 300 60
ESI-MS: Electrospray ionization mass spectrometry
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fragment, the cation with m/z 223 was formed. A separation of the 
hydrazine fragment from the triazole cycle was caused the cation with 
m/z 197 formation. The cation with m/z 105 after the release of the 
pyridinic cycle and methylene group appears. Another cation (m/z 105) 
may was appeared with the release of the benzene cycle and methylene 
group. Two cations (m/z 149 and 132) were formed after the release 
of a thioacetate fragment linked with the residues of the triazole cycle.
Piperidin-1-ium 2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-
yl)thio)acetate
The fragmentation of this compound described on the base of the mass 
spectra presented at Fig. 3 and Table 3.
The peak of the quasimolecular ion of an acid form protonated on 
triazole nitrogen was seen at both 100 V and 200 V and has m/z 302 
(Figs. 4 and 5).
The peak of protonated piperidine salt with m/z 387 was detected at 
100 V. The peak of the dimer ion with m/z 603 was detected in the 
mass spectrum at the 100 V. The cation with m/z 284 was formed at 
the release of the OH-group from the quasimolecular ion of the acid 
form of the active pharmaceutical ingredient. The cation with m/z 256 
at the further separation of the CO-fragment occurs. Two variants of 
the cation with m/z 242 at further release of the methylene group and 
cyclization were formed. The cation with m/z 214 at the separation 
of sulfur and partial reduction of the triazole cycle was formed. With 
partial disintegration of the triazole cycle, the cation with m/z 189 
occurs and it turns into the cation with m/z 170 with further release of 
ammonia. With destruction of the furan ring and partial decomposition 
of the triazole cycle, cations with m/z 149 and 121 sequentially occur.
Morpholin-4-ium 2-((5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)
acetate
According to mass spectra (Fig. 6 and Table 4) in the acidic medium of 
the eluent, morpholinium salt turns into the corresponding acid, which 
forms the cation with m/z 237 when linked with a proton of hydrogen.
At 100 V, release of carbon oxide (IV) leads to the occurrence of the 
positive ion with m/z 193 (Fig. 7).
Separation of the pyridinic cycle and methyl group results in the 
formation of the cation with m/z 102, while partial destruction of 
Fig. 2: Proposed fragmentation pattern of the morpholin-4-ium 
2-((4-(2-methoxyphenyl)-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)
thio)acetate at 200 V
Table 3: The values of ions m/z of the piperidin-1-ium 
2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl) thio) acetate 
and relative abundance at 100V and 200V
100 V 200 V
m/z Abundance, % m/z Abundance, %
302.00 100.0 105.10 3.4
304.00 6.8 121.10 8.0
387.10 3.3 149.00 5.0







Table 4: The values of ions m/z of the morpholin-4-ium 
2-((5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl) thio) acetate and 
relative abundance at 100 V and 200V
100 V 200 V
m/z Abundance, % m/z Abundance, %
102.20 2.6 103.00 1.7
134.00 1.2 105.10 100.0
193.00 3.1 118.10 3.8













Fig. 3: Mass spectra of the piperidin-1-ium 2-((5-(furan-2-yl)-4-
phenyl-4H-1,2,4-triazol-3-yl)thio)acetate at 100 and 200 V
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the triazole cycle creates the cation with m/z 134. The formation of 
cation with m/z 219 was occured by elemination of the  OH group from 
quasimolecular ion at 200 V (Fig. 8).
On subsequent CO cleavage, cation with m/z 193 was appeared. It 
creates cation with m/z 191 in the subsequent dehydrogenation. The 
cation with m/z 118 was formed at isolation of the pyridine moiety. 
This cation may also form a cation radical with m/z 119. Then, cation 
radicals with m/z 103 and 105 after isolation methyl group appeared. 
Removal of the methylene group from the cation with m/z 191 leads to 
the formation of a cation with m/z 179. Further, the cation radical with 
m/z 178 was formed, which may be having two resonance forms. Next, 
release of the SH and complete or partial reduction of the triazole cycle 
Fig. 4: Proposed fragmentation pattern of the piperidin-1-ium 
2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate at 100 V
Fig. 5: Proposed pathways for the dissociation of piperidin-1-ium 
2-((5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate and 
theoretical monoisotopic masses of ions at 200 V
Fig. 6: Mass spectra of morpholin-4-ium 2-((5-(pyridin-4-yl)-4H-
1,2,4-triazol-3-yl)thio)acetate at 100 and 200 V
Fig. 7: Proposed fragmentation pattern of the morpholin-4-ium 
2-((5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate at 100 V
Table 5: The values of ions m/z of the morpholin-4-ium 
2-((5-(morpholinomethyl)-4-phenyl-4H-1,2,4-triazol-3-yl) 
 thio) acetate and relative abundance at 100 V and 200V
100 V 200 V
m/z Abundance, % m/z Abundance, %
335.10 100.0 100.10 100.0
669.10 5.9 101.10 6.0
670.10 2.1 105.10 2.0
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forms cation radical with m/z 150 and m/z 149, respectively. Further, 
partial destruction of the triazole cycle leads to the cation radical with 
m/z 123. Removal of the pyridine cycle from the cation with m/z 191 
and partial and complete reduction of the triazole cycle leads to the 
formation of a two cations with m/z 118 and 119. Next, release of the 
methyl group forms cations with m/z 103 and 105, respectively.
Morpholin-4-ium 2-((5-(morpholinomethyl)-4-phenyl-4H-1,2,4-
triazol-3-yl)thio)acetate
The mass spectra are shown in Fig. 9 and Table 5.
At 100 V, the peak of the quasimolecular ion of the protonated acid form 
of the active pharmaceutical ingredient with m/z 335 was observed 
(Fig. 10). Besides, there was an ion with m/z equal 669 which was dimer. 
At addition to it of the potassium ion, the ion with m/z=707 occurs.
At 200 V, ions with m/z=357 and 373 in the mass spectrum were 
observed, they correspond an adduct of the acid form of the 
substance with cations of sodium [M + Na]+ and potassium [M 
+ K]+, respectively (Fig. 11). Separation of the morpholine cycle 
from the quasimolecular ion results in the formation of the cation 
with m/z 236. With further release of the carbon oxide (IV) and 
further cyclization, the cation radical with m/z 189 was formed. 
With the release of the phenyl fragment and partial destruction 
of the morpholine fragment, the cation with m/z 173 results from 
the quasimolecular cation was formed. With further release of the 
acetate fragment, the cation with m/z=131 appears. The cation 
radical ion with m/z=248 occurs from the quasimolecular ion when 
the link between sulfur and carbon of 1,2,4-triazole was broken, 
as well as with the reduction of the triazole cycle. With further 
release of the methylene group and oxygen of the morpholine cycle, 
the radical cation with m/z 202 appears, while with destruction of 
1,2,4-triazole cycle the morpholine-methylene cation with m/z=100 
may was formed. With the release of the methylene-morpholine 
fragment, the cation with m/z=117 was formed. With further release 
of the methyl group and reduction of the triazole cycle, the cation 
with m/z=105 was formed.
Morpholin-4-ium 2-((4-ethyl-5-(morpholinomethyl)-4H-1,2,4-
triazol-3-yl)thio)acetate
The mass spectra are presented in Fig. 12 and Table 6.
At 100 V, the peak of the quasimolecular ion of the acid form of 
the active pharmaceutical ingredient with m/z 287 was observed 
(Fig. 13). Furthermore, a dimer ion with m/z 573 as well as adducts 
of the dimer ion with sodium (M/z=595) and potassium (m/z=611) 
were observed.
A quasimolecular ion was present at 200 V. Ions with m/z 309 and 325 
were observed, which corresponds, respectively, to the adducts of the 
acid form with the ion of sodium [M + Na]+ and potassium [M + K]+ 
(Fig. 14). With destruction of 1,2,4-triazole cycle of the quasimolecular 
ion, the methylene-morpholine cation with m/z=100 was formed. The 
Fig. 8: Proposed fragmentation pattern of the morpholin-4-ium 
2-((5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetate at 200 V
Fig. 9: Mass spectra of morpholin-4-ium 2-((5-(morpholinomethyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate at 100 and 200 V
Table 6: The values of ions m/z of morpholin-4-ium 
2-((4-ethyl-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yhe l) 
thio) acetate and relative abundance at 100 V and 200V
100 V 200 V




100.10 3.6 100.10 100.0
287.00 100.0 101.00 6.0
573.20 1.4 170.00 2.3
595.10 1.5 188.00 2.1
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separation of the morpholine fragment from the quasimolecular ion, 
the cation with m/z=200 was formed. With further separation of the 
methylene group, we observed the ion with m/z=188. Separation of 
OH-group results in occurrence of the cation with m/z=170. The cation 
with m/z=142 at the loss of CO appeared. Next, release of the ethyl 
group results the ion with m/z=114.
Morpholin-4-ium 2-((4-methyl-5-(morpholinomethyl)-4H-1,2,4-
triazol-3-yl)thio)acetate
The mass spectrum of this substance under the voltage of 100 V (Fig. 15 
and Table 7) of the fragmentor showed the peak of the quasimolecular 
ion of the acid form with m/z=273, as well as the adduct of the 
potassium cation ([M + K]+) m/z=311, dimer cation ([2M]+) with m/
z=545, and dimeric adduct with potassium cation m/z=583 ([2M + K]+).
Fig. 10: Proposed fragmentation pattern of the morpholin-4-ium 
2-((5-(morpholinomethyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)
acetate at 100 V
Fig. 11: Proposed fragmentation pattern of the morpholin-4-ium 2-((5-(morpholinomethyl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate at 
200 V
Table 7: The values of ions m/z of morpholin-4-ium 
2-((4-methyl-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)  
thio) acetate abundance at 100 V and 200 V




100.20 2.3 100.20 100.0
273.10 100.0 174.10 1.3
311.00 9.9 186.10 1.9
545.10 19.1 273.10 17.9
583.10 2.5
309
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Adducts with sodium ions were also observed, but their intensity was 
<1.0. With fragmentation of the quasimolecular ion, the morpholine-
methylene cation with m/z=100 was formed (Fig. 16).
Under the voltage of 200 V (Fig. 17) of the fragmentor, the quasimolecular 
ion of the acid form of the substance was observed which forms the 
morpholine-methylene cation with m/z=100 with cleavage of the 
1,2,4-triazole cycle. Release of the morpholine fragment results in the 
formation of the cation with m/z=186. Then, the methylene group was 
separated and the cation with m/z=174 was formed.
Zinc 2-((5-(2-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetate
There were mass spectra of this compound at Fig. 18 and Table 8.
At the voltage of 100 V, the cation with m/z=266 was observed that 
corresponds to the quasimolecular ion of the acid form of the active 
pharmaceutical ingredient (Fig. 19). On addition of the sodium 
cation, the adduct with m/z=288 ([M + Na]+) was formed. With 
separation of carbon oxide (IV), the cation with m/z=220 appeared.
The same cations were observed at the voltage of 200 V of 
the fragmentor (Fig. 20). Besides, with fragmentation of the 
quasimolecular ion with the release of the thioacetate group from 
the triazole fragment and methyl radical from the methoxy group, 
the radical cation with m/z=161 was formed. With further release 
of OH, the cation with m/z=144 was formed. The cation with 
m/z=144 can also formed with the release of a methoxyphenyl 
radical and hydroxyl group from the quasimolecular cation. 
With destruction of the 1,2,4-triazole-ylthioacetate radical, 
the methoxyphenyl cation with m/z=107 was formed. With the 
release of methoxyphenyl radical and carbon dioxide, the ion 
with m/z=130 was formed. Separation of the OH-group from the 
quasimolecular ion results in the formation of the cation with 
m/z=248 which transforms into the relevant ion with m/z=220 
with CO separation. With further separation of two methylene 
Fig. 12: Mass spectra of morpholin-4-ium 2-((4-ethyl-5-
(morpholinomethyl)-4H-1,2,4-triazol-3-yhe l)thio)acetate at 
different fragmentor voltage (100 and 200 V)
Fig. 13: Proposed fragmentation pattern of the morpholin-4-ium 
2-((4-ethyl-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)
acetate at 100 V
Fig. 14: Proposed fragmentation pattern of the morpholin 
morpholin-4-ium 2-((4-ethyl-5-(morpholinomethyl)-4H-1,2,4-
triazol-3-yhe l)thio)acetate at 200 V
Fig. 15: Mass spectra of morpholin-4-ium 2-((4-methyl-5-
(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)acetate at 
different fragmentor voltage (100 and 200 V)
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groups, the cation with m/z=193 appears. Further, cyclization 
and separation of a hydrogen atom results in the formation of the 
radical cation with m/z=191. With separation of one methylene 
group from the cation with m/z=220, the radical cation with 
m/z=207 appears which transforms into the radical cation with 
m/z=205 at cyclization.
During the fragmentation of the quasimolecular ion with partial 
destruction of the triazole cycle  three-membered diazo heterocycles 
with m/z=151 and 149 were formed. With the release of one nitrogen 
atom, it transforms into the radical cation with m/z=133 having two 
resonance forms.
A part of the triazole cycle with thioacetate residue from the 
quasimolecular ion forms the radical cation with a three-membered 
diazo heterocycle with m/z=132. Next, with the release of one nitrogen 
atom new radical cation with m/z=119 appears. At separation of 
another nitrogen atom, the cation with m/z=105 appears. Then, it 
transforms into the radical cation with m/z=104 at release of one 
hydrogen atom. Next, at the release of another hydrogen atom, the 
cation with m/z=103 was formed.
CONCLUSIONS
ESI-MS fragmentation of salts of 1,2,4-triazolylthioacetate acids as active 
pharmaceutical ingredients of pharmaceutical formulations at different 
Fig. 16: Proposed fragmentation pattern of the morpholin-4-ium 
2-((4-methyl-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)
acetate abundance at 100 V
Fig. 17: Proposed fragmentation pattern of the morpholin-4-ium 
2-((4-methyl-5-(morpholinomethyl)-4H-1,2,4-triazol-3-yl)thio)
acetate abundance at 200 V
Fig. 18: Mass spectra of zinc 2-((5-(2-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio) acetate at different fragmentor voltage (100 and 200 V)
Table 8: The values of ions m/z of zinc 
2-((5-(2-methoxyphenyl)-4H-1,2,4-triazol-3-yl) thio) acetate 
abundance at 100 V and 200V
100 V 200 V
m/z Abundance m/z Abundance
157.00 0.9 101.90 1.5
220.00 1.1 103.00 12.1
266.00 100.0 104.10 39.2
277.00 1.1 117.00 1.8
288.00 1.4 118.10 2.6
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fragmentor voltage has been studied. The mass spectra of the salt of series 
1,2,4-triazolylthioacetate acids have been shown. The fragmentation 
pathways for the salts of series 1,2,4-triazolylthioacetate acids have 
been provided. There are several basic regularities, the fragmentation 
of the investigated derivatives of 1,2,4-triazole: Few studied substances 
form dimeric cations, some of them creates adducts with sodium and 
potassium, and the destruction of triazole cycle may lead to the formation 
of three-membered heterocycles. Studying the fragmentation of the 
indicated substances can be used for detecting the mentioned substances, 
as well as for confirming the structure of new compounds with the mass 
spectrum based on the patterns described above.
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